{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"3.7","value":"2.9"},{"groupId":"OG001","lowerLimit":"9.2","upperLimit":"17.5","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index (FOSI-18) is a questionnaire, for completion by patients, designed to assess the impact of cancer therapy on ovarian cancer-related physical, emotional and treatment-related symptoms, and is based on numerical point scoring of symptoms. The questionnaire is designed to evaluate changes in the total score in individual assessments over time. This study looked at the time to an 8-point reduction in the total score as an indicator of improvement in disease-related symptoms on cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG001","title":"Placebo Tablets"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat: All patients randomized","reportingStatus":"POSTED","timeFrame":"Screening, Day 1 of each treatment cycle, Treatment Discontinuation visit, and 28-day Follow-up visit. Total follow-up was up to approximately 6.4 years.","title":"Time to an 8-point Decrease in the Total Score of the FOSI-18","type":"SECONDARY","unitOfMeasure":"Months"}